Urinary artificial sphincter ZSI 375 for treatment of stress urinary incontinence in men: 5 and 7 years follow-up report
In press - Corrected proof
Article Type: SURGICAL TECHNIQUE
AuthorsChristophe Llorens, Tobias Pottek
This is a retrospective, non-randomised study.
The aim of this study was to evaluate safety and efficacy of artificial urinary sphincter ZSI 375 inserted in male patients with stress urinary incontinence (SUI).
Between May 2009 and January 2017, 45 men with SUI underwent ZSI 375 device insertion. Operations were performed in two French centres by one surgeon. Complications and pad used to manage continence were recorded.
From May 2009 to January 2012, 45 patients with a mean age of 70.42 years underwent placement of the ZSI 375 device in France. The most common cause for incontinence was radical prostatectomy (RP, 33/45 patients, 73.33%). The minimal period of incontinence was 6 months. Twenty-seven out of 45 patients (60.00%) had a severe incontinence (at least four pads per day), 13 patients (28.89%) had moderate incontinence (three pads per day) and five patients (11.11%) had two pads per day. With a long follow-up, the ZSI 375 device was considered to be successful in 73.33% patients after 5 years (60 months) and 72% of patients after 7 years (84 months). The infection rate was 2.2 % affecting one in 45 patients. Six out of 45 patients presented a urethral erosion (13.33%). Mechanical failure with a revision occurred in three patients (6.67%).
The ZSI 375 device is a safe and effective device to treat severe SUI in men.
- • Accepted on 13/04/2017
- • Available online on 18/05/2017
This article is available as full text PDF.
Since 1973, the artificial urinary sphincter (AUS) manufactured by American Medical System (AMS), Minnesota, USA is the gold standard for the treatment of urinary incontinence (UI) (1, 2). AMS 800 was improved with a double cuff (3), but it is a complex procedure, without any option to adjust the issued pressure or to adjust the cuff in case of urethral atrophy (4, 5).
ZSI 375 (Zephyr Surgical Implants, Geneva, Switzerland) was designed to facilitate US insertion. It is a pre-connected two-component device. It has no abdominal reservoir so as to reduce operating time and to avoid abdominal incision and dissection in scarred retroperitoneum (6, 7). The cuff is adjustable and the pressure can be increase for continence control (6, 7). First, ZSI 375 insertion was 7.5 years ago. The aim of the present study was to report our experience with this AUS in 45 male patients to assess its safety and efficacy.
Patients and methods
We performed a retrospective study of patients who underwent ZSI 375 placement in two French centres by one surgeon. Indication for ZSI 375 insertion was for moderate stress UI (two to three pads/day) and severe stress incontinence (four and more pads/day). All patients had failed previous rehabilitation by pelvic floor training and electrostimulation. The preoperative evaluation included patient history, pad use, a physical examination and cystoscopy looking for stricture, urine analysis and urodynamic examination to exclude an overactive bladder.
Between May 2009 and January 2012, 45 men with stress urinary incontinence underwent ZSI 375 device insertion. Patients reported incontinence after RP, RP and radical radiotherapy (RP + RR), transurethral resection of the prostate (TURP), radiotherapy and transurethral resection of the prostate (RT + TURP), radical cystectomy and an orthotopic neobladder formation and neurological condition (medullar RT). The patients were followed up until January 2017.
ZSI 375 is an AUS mainly made from medical grade silicone (
Artificial Urinary Sphincter ZSI 375.
The implantation procedure was carried out under general anaesthesia with patients in the lithotomy position. A 16F Foley catheter was placed for guidance and to calibrate the urethra. The surgical technic consists of a perineal incision for cuff placement and inguinal incision for pump unit scrotal placement. During the procedure, the sphincter closure pressure set ranged from 60 to 70, from 70 to 80 or rom 90 to 100 cmH2O.
A 12F Foley catheter was inserted at the end of the procedure for 24 hours. Patients were discharged 24-48 hours after procedure. The device was activated 8 weeks later. After activation, the issued pressure could be increased in situ by trans-scrotal injection of saline into the compensation pouch; 1 ml saline increased pressure by 10 (range 8-12) cmH2O.
Assessment of postoperative continence
Urine analysis, bladder ultrasonography to evaluate residual urine volume and flow rate measurements were performed after sphincter activation, 3 months, 6 months after activation and every year up to January 2017.
Patients recorded number of pads used per day in a 7-day diary before their visits. Total continence was given by use of zero pads (i.e. completely dry), and social continence as daily use of zero to one pad. Incontinence was given by daily use of more than one pad.
Success was defined as social continence (zero to one pad per day) and improvement as a decrease in daily pad use (usually two pads per day).
The necessity of issued pressure adjustment was determined according to each patient’s requirements.
Forty-five patients with a mean age of 70.42 (53-89) years underwent ZSI 375 AUS insertion. The minimal period of incontinence was 6 months. Twenty-seven patients (60.00%) had a severe incontinence (at least four pads per day), and 13 patients (28.89%) had a moderate incontinence (three pads per day). Five patients (11.11%) had two pads per day. Incontinence was secondary to radical laparoscopic or open prostatectomy (RP) (33/45 patients, 73.33%), RP with adjuvant RT (RP + RR) (2/45 patients, 4.45%), RR + TURP (1/45 patients, 2.22%). The other causes of incontinence included TURP (seven patients, 15.56%), radical cystectomy (1/45 patients, 2.22%) and medullar RT (1/45 patients, 2.22%). Three patients (6.67%) had experienced previous AMS 800 insertion and failure before ZSI 375 insertion. We lost sight of two patients (4.44%) after 1 year and 4 years. Four out of 45 patients (8.89%) died from ageing after a mean follow-up of 5 years. Pre- and postoperative clinical data are presented in
Continence rates before and after device implantation
|Before implantation||1 years follow-up||3 years follow-up||5 years follow-up||7 years follow-up|
|n = number of patients.|
|Pads used/day, n (%)|
|None||0||10 (22.22)||11 (24.44)||11 (24.44)||5 (20.00)|
|1||0||28 (62.22)||22 (48.89)||22 (48.89)||13 (52.00)|
|2||5 (11.11)||1 (2.22)||1 (2.22)||1 (2.22)||1 (4.00)|
|3||13 (28.89)||3 (6.66)|
|≥4||27 (60.00)||3 (6.66)|
|Success 0 or 1 pad, n (%)||38 (84.44)||33 (73.33)||33 (73.33)||18 (72.00)|
|Failure, n (%)||7 (15.56)||12 (26.67)||11 (24.44)||3 (12.00)|
|Revision rate||1 (2.22)||2 (4.44)||3 (6.67)||2 (8.00)|
|Lost sight||0||1 (2.22)||2 (4.44)||2 (8.00)|
|Dead||0||0||4 (8.89)||2 (8.00)|
Implantation and recovery was uneventful in 35 patients (77.78%). No patient experienced bladder overactivity after device activation.
Complications occurred in 10 patients (22.22%): one case (2.22%) of scrotal infection, six cases (13.33%) of urethral erosion and three cases (6.67%) of mechanical failure leading to a revision. Regarding the mechanical failure, one case (2.22%) was due to saline solution leakage and two cases (4.44%) due to armed tubing breakage. The case of saline leakage (2.22%) was due to accidental “micro” intraoperative injury of the silicone tube with the needle. The two cases (4.44%) of armed tubing broken were early in the experience and lead to a reinforcement of the armed tubing and a change in the manufacturing process.
One patient (2.22%) did not have any complication but a persistent incontinence with the use of two pads per day.
The ZSI 375 implantation-related complications by cause of UI are presented in
ZSI 375 implantation related complications by aetiology of urinary incontinence
|Aetiology of incontinence||Infections n, (%)||Urethral erosions n, (%)||Mechanical complications n, (%)|
|n = number of patients; RP = radical prostatectomy; RT = radiotherapy; TURP = transurethral resection of the prostate; RC = radical cystectomy.|
|RP||1 (2.22)||3 (6.67)||2 (4.44)|
|RP + RT||0||2 (4.44)||0|
|RT + TURP||0||1 (2.27)||0|
|Total||1 (2.22)||6 (13.33)||3 (6.67)|
Considering number of pads used per day, 38 out of 45 patients (84.00%) reached social continence after 1 year and 33 out of 45 patients (73.33%) after 5 years. One patient (2.22%) was considered as improved with two pads per day. Twenty-five patients (55.56%) have had a follow-up of 7 years with a nonsignificant decrease in the continence rate, and 18 out of 25 patients (72%) had a social continence (zero to one pad per day);
AMS 800 is considered the gold standard treatment for severe stress UI in men. But AMS 800 single cuff or double cuff is still a complex surgical procedure. After AUS AMS 800 activation, there is no option to adjust the issued pressure of the device or to adjust the cuff in case of urethral atrophy (4). The ZSI 375 AUS with adjustable issued pressure and adjustable cuff was designed and developed in the last 10 years to simplify the surgical procedure.
In this retrospective study, we report our first experience with ZSI 375 with a long follow-up period of 5 and 7 years. During the mean follow-up period of 60 months, the success rate was 73.33% and one patient (2.22%) improved with two pads per day when he used to wear more than four pads per day before ZSI 375 insertion. Only seven patients (15.56%) failed the treatment because of infection and urethral erosion. We also demonstrated that the total continence achieved with the ZSI 375 device was stable after 5 and 7 years. Previous studies showed good short-term results, which ranged from 87% to 94.2% (6-7-8). ZSI 375 efficacy is comparable with AMS 800 efficacy after 2 years follow-up period (≤90%) (4, 5) and in long-term period (9, 10).
Meanwhile, the operations were performed with first version of the ZSI 375 device and we included the patients from the surgeon’s learning curve in terms of preparation and procedure in the study; the present series confirms the simplicity of the ZSI 375 surgical procedure.
Unfortunately, a history of RR therapy was associated with complications in our study in agreement with studies about AMS 800 (11, 12). Three patients who underwent pelvic irradiation before the ZSI 375 implantation presented urethral erosion after ZSI 375 activation.
Our short-term complication rate was comparable with AMS 800 (4, 13, 14). Seven out of 10 complications took place within first 12 months after ZSI 375 insertion, and three out of 10 appeared within 36 months after surgical procedure.
AUS infection occurring without cuff erosion is not common, as most of the erosion will lead to perineal and scrotal infection (15). Our infection rate was 2.22% (one patient had a scrotal infection) in accordance with AMS 800 rate 1-8% (4, 14, 16, 17).
Mechanical failure leading to a revision occurred in three patients (6.67%). One patient presented a leakage at activation of the device and two patients patients presented an armed tubing breakage during the third year of functioning. The leakage was accidental after needle piercing the armed tubing during the procedure (piercing showed by expertise of the devise after removal). The two armed tubing breakage were due to a lack of reinforcement and led to an early change of the mould and manufacturing process. The rate of mechanical failure of ZSI 375 in our series is comparable with that of AMS 800 (4, 17-18-19).
A last interesting feature of the ZSI 375 device is the absence of an abdominal reservoir leading to an easy surgical procedure reducing risk linked to perineal intrusion after RP.
Our study reports our first experience with the ZSI 375 device implantation in a series of 45 patients and with a follow-up period of 5 years for 45 patients and 7 years for 25 patients. It was long enough to identify all potential complications and to establish the safety and efficacy of the ZSI 375 device. Result can be improved regarding the experience we acquired with the ZSI 375 device, and the use of the last version of the ZSI 375 PF device, prefilled, is now available.
But the present study has further limitation: its design was retrospective, the sample size was small and assessment of continence was based on pad number and not on pad weight.
The ZSI 375 AUS was effective in treating moderate to severe male UI. A large majority (84.44%) of the patients presented a social continence after 12 months with a stabilisation at 73.33% after 3 and 5 years and 72.00% after 7 years.
We encountered low complication rate. The easy surgical procedure with adjustable cuff and adjustable issued pressure make the ZSI 375 device an attractive option to treat severe male urinary stress incontinence.
Scott FB Bradley WE Timm GW Treatment of urinary incontinence by implantable prosthetic sphincter. 1973 1 252 259
Herschorn S Bruschini H Comiter C et al. Surgical treatment of stress incontinence in men. 2010 29 179 180
Brito CG Mulahy JJ Mitchell ME et al. Use a double cuff AMS 800 urinary sphincter for severe stress incontinence. 1993 149 283 285
Ostrowski I Śledź E Ciechan J et al. Current interventional management of male stress urinary incontinence following urological procedures. 2015 68 3 340 347
James MH McCammon KA Artificial urinary sphincter for post-prostatectomy incontinence: a review. 2014 21 6 536 543
Vakalopoulos I Kampantais S Laskaridis L Chachopoulos V Koptsis M Toutziaris C New artificial urinary sphincter devices in the treatment of male iatrogenic incontinence. 2012 2012 439372.
Staerman F G-Llorens C Leon P Leclerc Y ZSI 375 artificial urinary sphincter for male urinary incontinence: a preliminary study. 2013 Apr 111 4 Pt B E202 E206
Sandul A Martins FE Barros P Lopes TM Llorens C The ZSI 375 artificial urinary sphincter: a new device for male urinary incontinence. November 2010; Vilamoura, Portugal.
Patki PI Hamid R Shah PJ Craggs M Long-term efficacy of AMS 800 artificial urinary sphincter in male with urodynamic stress incontinence due to spinal cord lesion. 2006 May 44 5 297 300
Gülpınar O Süer E Gökce MI Haliloğlu AH Öztürk E Arıkan N Functional outcomes and long-term durability of artificial urinary sphincter application: review of 56 patients with long-term follow-up. 2013 54 6 373 376
Sousa-Escandón A Cabrera J Mantovani F et al. Adjustable suburethral sling (male remeex system) in the treatment of male stress urinary incontinence: a multicentric European study. 2007 52 5 1473 1479
Kim SW Walsh R Berger Y Kim JH Male readjustable sling (MRS) system for postprostatectomy incontinence: experiences of 2 centers. 2016 Feb 88 195 200
Hajivassiliou CA A review of the complications and results of implantation of the AMS artificial urinary sphincter. 1999 35 1 36 44
Andreasson A Fall M Persson E Stranne J Peeker R High revision rate following artificial urethral sphincter implantation. 2014 48 6 544 548
Montague DK Artificial urinary sphincter: long-term results and patient satisfaction. 2012 2012 835290.
Clemens JQ Schuster TG Konnak JW McGuire EJ Faerber GJ Revision rate after artificial urinary sphincter implantation for incontinence after radical prostatectomy: actuarial analysis. 2001 Oct 166 4 1372 1375
Lai HH Hsu EI Teh BS Butler EB Boone TB. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. 2007 177 3 1021 1025
Petrou SP Elliott DS Barrett DM Artificial urethral sphincter for incontinence. 2000 56 3 353 359
Van der Aa F Drake MJ Kasyan GR Petrolekas A Cornu JN Young Academic Urologists Functional Urology Group. The artificial urinary sphincter after a quarter of a century: a critical systematic review of its use in male non-neurogenic incontinence. 2013 63 4 681 689